Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Dana Aftab sold 47,918 shares of Exelixis stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the sale, the executive vice president owned 616,106 shares in the company, valued at approximately $27,416,717. This represents a 7.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Dana Aftab also recently made the following trade(s):
- On Thursday, February 19th, Dana Aftab sold 29,873 shares of Exelixis stock. The shares were sold at an average price of $44.35, for a total transaction of $1,324,867.55.
Exelixis Trading Down 1.1%
Shares of NASDAQ:EXEL opened at $44.28 on Friday. The company has a 50 day moving average of $44.09 and a 200-day moving average of $41.39. The firm has a market cap of $11.50 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.01 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62.
Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm's revenue for the quarter was up 5.6% compared to the same quarter last year. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Sunday, February 22nd. Morgan Stanley raised their target price on shares of Exelixis from $48.00 to $49.00 and gave the stock an "equal weight" rating in a report on Monday, February 2nd. UBS Group set a $41.00 target price on Exelixis in a research report on Monday, January 5th. Stifel Nicolaus lifted their target price on shares of Exelixis from $43.00 to $44.00 and gave the company a "hold" rating in a research note on Wednesday, February 11th. Finally, TD Cowen restated a "buy" rating on shares of Exelixis in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $47.11.
Read Our Latest Report on Exelixis
Institutional Investors Weigh In On Exelixis
A number of institutional investors have recently made changes to their positions in EXEL. Motiv8 Investments LLC acquired a new stake in Exelixis in the fourth quarter worth $26,000. Richardson Financial Services Inc. raised its position in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 292 shares during the period. Anchor Investment Management LLC raised its holdings in Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock worth $25,000 after buying an additional 500 shares during the period. Acumen Wealth Advisors LLC bought a new stake in shares of Exelixis during the fourth quarter worth $29,000. Finally, Root Financial Partners LLC acquired a new stake in shares of Exelixis during the third quarter worth $28,000. 85.27% of the stock is owned by institutional investors and hedge funds.
Exelixis Company Profile
(
Get Free Report)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
